The effect of toremifene on the expression of genes in a rat mammary adenocarcinoma.
Toremifene, apart from its partial estrogen antagonism, exerts multiple and varied effects on a variety of genes involved in the control of signalling and apoptosis. After three weeks of exposure of R3230AC hosting rats to therapeutical oral doses of toremifene distinct changes in steroid receptors, P-glycoprotein, p53 and Bc1-2 expression and protein S100 levels occurred, which may contribute to our understanding of the mechanisms of action of this antiestrogen.
Kellen
J A
JA
Sunnybrook Health Sciences Centre, Department of Clinical Biochemistry, University of Toronto, Ontario, Canada.
Mirakian
A
A
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000378:metabolism; D000818:Animals; D018931:Antineoplastic Agents, Hormonal / Q000494:pharmacology*; D001835:Body Weight; D005260:Female; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D008325:Mammary Neoplasms, Experimental / Q000188:drug therapy* / Q000378:metabolism; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000032:analysis; D051381:Rats; D011916:Rats, Inbred F344; D009418:S100 Proteins / Q000032:analysis; D017312:Toremifene / Q000494:pharmacology*; D016159:Tumor Suppressor Protein p53 / Q000032:analysis
D018931:Antineoplastic Agents, Hormonal; D019253:Proto-Oncogene Proteins c-bcl-2; D009418:S100 Proteins; D016159:Tumor Suppressor Protein p53; D017312:Toremifene